Experimental T-Cell Therapy Achieves Remission in Teen with Advanced Kidney Cancer
In Germany, an experimental T-cell therapy has shown remarkable success in a 17-year-old boy with relapsed kidney cancer that had spread to multiple organs. The treatment, detailed in the New England Journal of Medicine, targets a protein called PRAME found…
Fort Myers Naples, FL, August 12, 2026 —
An experimental T-cell therapy has resulted in a complete remission for a 17-year-old boy battling relapsed kidney cancer that had metastasized to multiple organs. The groundbreaking treatment, described in the New England Journal of Medicine, represents a novel approach to tackling solid tumors by targeting a protein known as PRAME, which is found on the surface of cancer cells.
The patient, who received the therapy in Germany, was administered a single infusion. Subsequent monitoring revealed that the cancer was no longer detectable. A year after the treatment, the teenager remains in complete remission, indicating a significant and sustained response to this innovative therapeutic strategy.
This development is particularly significant as it demonstrates the potential of T-cell therapies, which have shown promise in blood cancers, to effectively treat solid tumors, especially in pediatric patients. The therapy’s focus on the PRAME protein offers a new avenue for research and treatment development in cases where conventional therapies have failed.
Further research will be necessary to determine the long-term efficacy and applicability of this PRAME-targeting T-cell therapy across a wider patient population and different types of solid tumors.
Story summarized from the original created by Veronique Greenwood on time.com, see more information here.
Media gallery
